Sana Biotechnology, Inc. (SANA)
NASDAQ: SANA · Real-Time Price · USD
1.650
+0.050 (3.13%)
At close: Dec 20, 2024, 4:00 PM
1.720
+0.070 (4.24%)
After-hours: Dec 20, 2024, 5:30 PM EST
Sana Biotechnology Employees
Sana Biotechnology had 328 employees as of December 31, 2023. The number of employees decreased by 93 or -22.09% compared to the previous year.
Employees
328
Change (1Y)
-93
Growth (1Y)
-22.09%
Revenue / Employee
n/a
Profits / Employee
-$932,338
Market Cap
368.39M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 328 | -93 | -22.09% |
| Dec 31, 2022 | 421 | 35 | 9.07% |
| Dec 31, 2021 | 386 | 121 | 45.66% |
| Dec 31, 2020 | 265 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ZimVie | 2,600 |
| AngioDynamics | 748 |
| Kamada | 378 |
| REGENXBIO | 344 |
| Prime Medicine | 234 |
| Personalis | 225 |
| Taysha Gene Therapies | 52 |
| Contineum Therapeutics | 31 |
SANA News
- 17 days ago - Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus - Seeking Alpha
- 26 days ago - Sana Biotechnology to Present at December 2024 Investor Conferences - GlobeNewsWire
- 4 weeks ago - Sana Biotechnology: The Story Becomes Murkier - Seeking Alpha
- 6 weeks ago - Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewsWire
- 6 weeks ago - Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025 - GlobeNewsWire
- 2 months ago - Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference - GlobeNewsWire
- 4 months ago - Sana Biotechnology to Present at September 2024 Investor Conferences - GlobeNewsWire
- 4 months ago - Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer - GlobeNewsWire